Chemical synthesis of IL-10 cytokine 90% cheaper than bioproduction, Provepep

By Dan Stanton

- Last updated on GMT

Chemical synthesis of IL-10 90% cheaper than bioproduction, Provepep

Related tags Chemical synthesis Peptide synthesis

Chemical synthesis of peptides and proteins can be done at a tenth of the cost of bioproduction says French chemistry specialist Provepep.

Last year​, France’s Provence Technologies acquired Synprosis, an API maker specialising in long-chain peptide synthesis through its peptide ligation technology.

The division has since been renamed Provepep and has announced this week that it has successfully chemically synthesized a bioactive homodimer form of IL-10, an anti-inflammatory cytokine, paving the way for chemical synthesis as an alternative  to  recombinant technology.

“Multiple interests can rise from the chemical synthesis of polypeptides and proteins,”​ Jean-Pierre Salles, the firm’s CSO told in-Pharmatechnologist. “Sequences can be chemically modified with the insertion of unnatural amino acids – for instance D amino acid. Such possibilities can provide new characteristics to proteins.”

Benefits of chemically synthesizing these products rather than using cell-lines include greater access to purer products and the ability to generate  reproducible results, but the major bonus is the cost saving potential, Salles said.

“Investment costs can be reduced by up to 90% compared to bioproduction. It takes between 100 and 200 million US Dollars to implement a biomanufacturing facility, whereas a chemical unit costs between 15 and 20 million dollars.”

This is because direct production costs in bioproduction are very much influenced by the downstream process, he said, specifically the isolation and purification steps.

“In the case of chemical synthesis, these are significantly simplified.” ​Furthermore, “chemical synthesis does not have the same constraints as bioproduction in terms of viral safety.”

The firm achieved the synthesis of IL-10 using its SEA ligation platform: a native chemical ligation which joins a bis(2-sulfanylethyl)amino peptide with a cysteinyl or hoocysteinyl peptide, giving access to proteins.

The SEA technology currently applies to non-glycosylated proteins with length ranging from 150 to 350 mer.

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Related suppliers

Follow us


View more